Fox Run Management L.L.C. Acquires Shares of 4,876 AstraZeneca PLC (NASDAQ:AZN)

Fox Run Management L.L.C. acquired a new stake in shares of AstraZeneca PLC (NASDAQ:AZNGet Rating) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 4,876 shares of the company’s stock, valued at approximately $284,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. MayTech Global Investments LLC purchased a new position in shares of AstraZeneca during the 3rd quarter worth approximately $25,000. Arlington Partners LLC purchased a new position in shares of AstraZeneca during the 4th quarter worth approximately $25,000. Addison Advisors LLC raised its stake in shares of AstraZeneca by 1,578.8% during the 4th quarter. Addison Advisors LLC now owns 554 shares of the company’s stock worth $32,000 after buying an additional 521 shares in the last quarter. AXA S.A. purchased a new position in shares of AstraZeneca during the 3rd quarter worth approximately $36,000. Finally, PSI Advisors LLC purchased a new position in shares of AstraZeneca during the 3rd quarter worth approximately $51,000. 20.46% of the stock is owned by hedge funds and other institutional investors.

AZN has been the subject of a number of analyst reports. DZ Bank raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Friday, February 11th. Stifel Nicolaus started coverage on AstraZeneca in a report on Monday, February 28th. They issued a “buy” rating on the stock. Morgan Stanley upped their price target on AstraZeneca from £102 ($127.42) to £111 ($138.66) in a report on Thursday, April 21st. JPMorgan Chase & Co. upped their price target on AstraZeneca from £100 ($124.92) to £120 ($149.91) in a report on Thursday, April 7th. Finally, SVB Leerink upped their price target on AstraZeneca from $65.00 to $70.00 and gave the stock an “outperform” rating in a report on Thursday, February 24th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $7,223.13.

Shares of AstraZeneca stock opened at $66.75 on Thursday. AstraZeneca PLC has a fifty-two week low of $52.97 and a fifty-two week high of $71.70. The firm has a market cap of $206.85 billion, a PE ratio of -208.59, a P/E/G ratio of 1.25 and a beta of 0.45. The business’s fifty day moving average is $64.95 and its two-hundred day moving average is $60.73. The company has a quick ratio of 0.76, a current ratio of 1.16 and a debt-to-equity ratio of 0.72.

AstraZeneca (NASDAQ:AZNGet Rating) last issued its quarterly earnings results on Thursday, April 28th. The company reported $0.95 earnings per share for the quarter, topping analysts’ consensus estimates of $0.87 by $0.08. AstraZeneca had a positive return on equity of 26.29% and a negative net margin of 2.56%. The company had revenue of $11.39 billion for the quarter, compared to analyst estimates of $10.96 billion. During the same quarter in the prior year, the company posted $0.81 EPS. The business’s revenue for the quarter was up 55.6% compared to the same quarter last year. Equities research analysts anticipate that AstraZeneca PLC will post 3.32 EPS for the current year.

The firm also recently declared a semi-annual dividend, which was paid on Monday, March 28th. Shareholders of record on Friday, February 25th were paid a dividend of $0.985 per share. This represents a dividend yield of 2.4%. The ex-dividend date of this dividend was Thursday, February 24th. This is a positive change from AstraZeneca’s previous semi-annual dividend of $0.45. AstraZeneca’s dividend payout ratio is currently -603.11%.

About AstraZeneca (Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Read More

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZNGet Rating).

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.